Brii Biosciences (HKSE:02137) Marketable Securities : HK$2,374.61 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Brii Biosciences's Marketable Securities for the quarter that ended in Dec. 2023 was HK$2,374.61 Mil.

Brii Biosciences's annual Marketable Securities increased from Dec. 2021 (HK$611.80 Mil) to Dec. 2022 (HK$2,017.69 Mil) and increased from Dec. 2022 (HK$2,017.69 Mil) to Dec. 2023 (HK$2,374.61 Mil).

Brii Biosciences Marketable Securities Historical Data

The historical data trend for Brii Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Marketable Securities Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

23.71

611.80

2,017.69

2,374.61

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial				611.80	296.89	2,017.69	2,462.57	2,374.61

Brii Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Brii Biosciences (HKSE:02137) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Brii Biosciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines